Remotely Controlled Miniature Biological Robots Could Be Used for MIS and Detection of Disease Biomarkers
|
By LabMedica International staff writers Posted on 23 Jan 2023 |

A team of researchers has developed remotely controlled miniature biological robots that could find potential applications in medicine, such as minimum invasive surgery or detection of cancer within the human body.
The hybrid “eBiobots” are the first to combine soft materials, living muscle and microelectronics, according to researchers at the University of Illinois Urbana-Champaign (Champaign, IL, USA), Northwestern University (Evanston, IL, USA) and collaborating institutions. They have described their centimeter-scale biological machines in the journal Science Robotics.
Researchers at the University of Illinois Urbana-Champaign had earlier developed biobots, which are small biological robots powered by mouse muscle tissue grown on a soft 3D-printed polymer skeleton. In 2012, the team had demonstrated walking biobots. In 2016, they had also demonstrated light-activated biobots which provided the researchers with some control. However, the inability to deliver the light pulses to the biobots outside of a lab setting limited their practical applications. This time, researchers at Northwestern University helped integrate tiny wireless microelectronics and battery-free micro-LEDs, allowing them to remotely control the eBiobots.
With the aim of providing freedom of movement to the biobots in order to make them suitable for practical applications, the researchers focused on eliminating bulky batteries and tethering wires. The eBiobots use a receiver coil to harvest power and provide a regulated output voltage to power the micro-LEDs. The researchers are able to send a wireless signal to the eBiobots that prompts the LEDs to pulse. The LEDs stimulate the light-sensitive engineered muscle to contract, moving the polymer legs so that the machines can “walk.” The micro-LEDs are so targeted in a way that they can activate specific portions of muscle, making the eBiobot turn in the desired direction.
Using computational modeling, the researchers optimized the eBiobot design and integrated the components for robustness, speed and maneuverability. The iterative design and additive 3D printing of the scaffolds enabled rapid cycles of experiments and improvement in performance, according to the researchers. The design offers potential for future integration of additional microelectronics, such as chemical and biological sensors, or 3D-printed scaffold parts for functions like pushing or transporting things that the biobots can encounter. The integration of electronic sensors or biological neurons could allow the eBiobots to sense and respond to biomarkers for disease, among other possibilities.
“Integrating microelectronics allows the merger of the biological world and the electronics world, both with many advantages of their own, to now produce these electronic biobots and machines that could be useful for many medical, sensing and environmental applications in the future,” said study co-leader Rashid Bashir, an Illinois professor of bioengineering and dean of the Grainger College of Engineering.
“In developing a first-ever hybrid bioelectronic robot, we are opening the door for a new paradigm of applications for health care innovation, such as in-situ biopsies and analysis, minimum invasive surgery or even cancer detection within the human body,” said co-first author Zhengwei Li, an assistant professor of biomedical engineering at the University of Houston.
Related Links:
University of Illinois Urbana-Champaign
Northwestern University
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







